BridgeBio Pharma BBIO

Kumar Haldea Revocabletrust U/A DTD 12/19/2018 (Director) plans to sell 120,000 BBIO shares, about $5.2M

Form
144
Filed
Importance
Routine
Document
Form 144
  1. Approximate sale date: Jul 1, 2025
  2. Broker: Morgan Stanley Smith Barney LLC Executive Financial Services
  3. Shares acquired by: Conversion Management Incentive Units
  4. 10b5-1 plan adopted: Mar 31, 2025

All of Kumar Haldea Revocabletrust U/A DTD 12/19/2018's insider filings, holdings and planned sales

Form 4s that likely executed this notice (SEC Tracker's match by person, company, dates and shares):

  • Sold 11,795 shares at $45.88 on Aug 8, 2025 · Form 4
  • Sold 8,205 shares at $46.71 on Aug 8, 2025 · Form 4
  • Sold 25,728 shares at $48.81 on Aug 20, 2025 · Form 4
  • Sold 14,525 shares at $51.15 on Sep 4, 2025 · Form 4
  • Sold 5,475 shares at $51.85 on Sep 4, 2025 · Form 4
  • Sold 14,558 shares at $51.16 on Sep 4, 2025 · Form 4
  • Sold 5,442 shares at $51.85 on Sep 4, 2025 · Form 4
  • Sold 16,800 shares at $53.16 on Sep 5, 2025 · Form 4
  • Sold 900 shares at $53.8 on Sep 5, 2025 · Form 4
  • Sold 2,300 shares at $51.96 on Sep 5, 2025 · Form 4
  • Sold 800 shares at $53.8 on Sep 5, 2025 · Form 4

Written from the Form 144 on EDGAR. AI can make mistakes. Check the filing.

Get an email when BridgeBio Pharma files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

Data on this page was fetched . The filing on SEC.gov is the record.